The adjuvant AS03 is stockpiled for future formulations with new and existing vaccines for the control of pandemic influenza virus. We previously reported the immunogenicity of an A/H5N1 vaccine extemporaneously mixed with the AS03 adjuvant for 42 days following vaccination. This report extends those findings to 1 year after vaccination.
T
he immune-enhancing adjuvant AS03 is available as a component of the U.S. National Prepandemic Influenza Vaccine Stockpile (1) . The adjuvant can be mixed at the point of use with a selected vaccine antigen to maximize protective antibody responses while minimizing the antigenic content (dose sparing). We recently published the safety and immunogenicity results of a multicenter, randomized, and double-blinded phase 1 trial of an influenza A/H5N1 virus vaccine mixed with the AS03 adjuvant. Antibody titers were measured through day 42 postvaccination (2) . We report here the kinetics of the homologous and heterologous antibody responses at 6 months and 12 months after vaccination.
Healthy consenting adult volunteers were randomized 2:1 to receive either adjuvanted or nonadjuvanted vaccine and then randomized into 1 of 3 groups (1:1:1) to receive 2 intramuscular doses of vaccine containing 3.75, 7.5, or 15 g of hemagglutinin (HA) spaced 21 days apart. The investigational subvirion inactivated monovalent vaccine was manufactured by Sanofi Pasteur, Inc. (Swiftwater, PA) from the clade 2.1.3.2 influenza A/H5N1 (A/ Indonesia/05/2005) PR8-IBCDC-RG2 virus. The AS03 adjuvant was manufactured by GlaxoSmithKline Biologicals (Rixensart, Belgium). The U.S. Department of Health and Human Services (HHS) Biomedical Advanced Research and Development Authority (BARDA) provided the vaccine and adjuvant from the National Prepandemic Influenza Vaccine Stockpile. Serum samples were collected on days 0 (prevaccination), 8, and 21 (all before second vaccination) and on days 29 and 42. To assess the kinetics of the antibody response, serum samples were also collected at 6 months (day 201) and 12 months (day 386) postvaccination to assess hemagglutination inhibition (HAI) and microneutralization (MN) antibodies using standard methodologies (3, 4) .
For all groups, the homologous virus (A/Indonesia/05/2005) serum HAI and MN antibody titers peaked on day 29 (day 8, postdose 2) and then declined precipitously. In the groups that received nonadjuvanted vaccine, the HAI and MN antibody titers at 6 months postvaccination had returned to baseline levels. Conversely, a majority of the AS03-adjuvanted vaccine recipients maintained MN antibodies at 12 months postvaccination, with the proportion of subjects with an MN titer of Ն1:40 to the homologous virus significantly increasing with increasing dose, at 58%, 79%, and 88% with 3.75-g, 7.5-g, and 15-g doses of the AS03-adjuvanted vaccine, respectively (P ϭ 0.0041, Cochran-Armitage trend test). In general, antibody titers as assessed by the MN assay were higher than antibody titers as assessed by the HAI assay, consistent with the observation that the MN assay is a more sensitive means of detecting anti-influenza antibody (4) . Only a minority (Ͻ20%) of the AS03-adjuvanted vaccine recipients had HAI levels of Ն1:40 at 12 months postvaccination (Table 1 and Fig. 1 ). Previous trials of persons vaccinated with 2 doses of AS03-adjuvanted H5N1 A/Indonesia/05/2005 vaccine have also demonstrated near 50% or higher seroprotective HAI and MN levels of Ն1:40 at 6 months (5, 6) and 15 months (7) postvaccination. We use the term seroprotection; however, it should be noted that a titer of Ն1:40 of HAI or MN antibody is generally considered but has not been proven to be a predictor of protection against H5N1 viruses in humans, as has been shown for seasonal influenza viruses (8, 9) .
We previously showed that the HAI and MN responses to the heterologous (Table 1 and Fig. 2) .
A repeated-measures mixed-effects model (with dose group, adjuvant group, and time as fixed effects, both two-and three-way interactions as fixed effects, and a block diagonal unstructured covariance structure for the repeated observations within a subject) was fit to the homologous antibody data to further investigate the dose-response relationship over time. This model confirmed a statistically significant effect of the adjuvant (P Ͻ 0.0001) and of dose (P ϭ 0.0002), demonstrating that there was a strong dose-response relationship between dosage of the AS03-adjuvanted vaccine and persistence of MN antibody to the homologous virus.
The data from this trial are intended to inform pandemic preparedness planning and the public health response to future pandemics regarding point-of-use mixing and matching of the AS03 adjuvant with vaccine antigens from different manufacturers. Such a strategy would allow for maximum flexibility, rapid and durable immunogenicity (i.e., protection), cross-reactivity to drifted viruses, and dose sparing of limited vaccine quantities in the face of an evolving pandemic. We did not evaluate the effect of homologous or heterologous booster doses and intervals, but such studies are also critical for pandemic planning.
In conclusion, the homologous seroprotective antibody responses as measured by the MN assay were persistent among a majority of the subjects receiving the AS03-adjuvanted vaccine, even 1 year after vaccination. Durable heterologous protection was also seen, but it was strain dependent. The HAI antibody level declined more steeply during the 1 year after vaccination, and these levels were not sufficient to predict protection, based on the protection extrapolated from seasonal influenza. If we make the assumption that MN antibodies are truly a better correlate of protection than HAI antibodies and further assume that achieving at least a 1:40 titer is a predictor of protection, we could anticipate that the majority of AS03-adjuvanted vaccine recipients would remain protected against the homologous virus at least 1 year after vaccination, even with a 3.75-g antigen dosage (i.e., antigensparing dosage), while the full dose (15 g) would protect a higher proportion (58% versus 88%) of recipients. On the other hand, the antibody responses were strain specific, and we cannot assume that protection would extend to the A/Vietnam/1203/204 and A/Hubei/01/2010 virus strains. Table 1 .
